Citations

Clear

3485 citation(s) found for "Sy, Sarah".

0757 Sleepiness Improvement With Once-Nightly Sodium Oxybate in Patients With and Without Prior Twice-Nightly Oxybate Use: Specialty Pharmacy Data Analysis
Herpel, Laura, Thorpy, Michael, Meskill, Sarah, Ruoff, Chad, BUYSMAN, ERIN, Carino, Diana, Vu, Michelle, Abaluck, Brian, Gudeman, Jennifer , Ruoff, Chad , Ruoff, Chad M , Herpel, Laura Bogan, Meskill, Sarah, Buysman, Erin K. , Abaluck, Brian

Mayo Clinic

SLEEPJ | May 9, 2026 | Volume: 49 | Issue: Supplement_1 | Pages: A338-A338

10.1093/sleep/zsag091.0756 Get It

Abstract Introduction Once-nightly sodium oxybate (ON-SXB) is approved to treat cataplexy or excessive daytime sleepiness (EDS) in patients ≥7 years of age with narcolepsy. ON-SXB demonstrated significant improvements in both objective (Maintenance of Wakefulness Test) and subjective (Epworth Sleepiness Scale [ESS] score) measurements of sleepiness in the REST-ON trial and via the ESS in the real-world REFRESH study. Assessing ON-SXB ESS data from a specialty pharmacy and outside of clinical studies further informs the generalizability of effectiveness. Methods Demographic and clinical data were collected from Optum Frontier Therapies pharmacy for patients with ≥1 filled ON-SXB prescription, ≥1 ON-SXB-related clinical assessment, and ≥1 follow-up ESS score (6/1/2023-9/30/2024). Participation in ESS assessment was voluntary. ESS scores were assessed for patients who switched from twice-nightly oxybate (TN-OXB) treatment (first ON-SXB prescription filled ≤30 days of last TN-OXB prescription [switch]) and those new to oxybate or with >30 days between TN-OXB and ON-SXB prescription fills (not-on-oxybate) who had ESS data at initial ON-SXB prescription and at each follow-up assessment. Results Of 452 identified patients, 215 had ≥1 follow-up ESS score (switch, n=82 [mean age, 38.4 years; female, 71%]; not-on-oxybate, n=133 [mean age, 40.0 years; female, 71%]). Of patients who had any prior oxybate use (switch, 100%; not-on-oxybate, 46%), the most common prior oxybate was mixed-salt oxybates (switch, 59%; not-on-oxybate, 70%). Stimulants/wake-promoting agents were taken by 51% of switch and 65% of not-on-oxybate patients. Baseline mean (SD) ESS scores were 11.3 (5.5) for switch and 12.5 (5.6) for not-on-oxybate patients; 23% of switch and 38% of not-on-oxybate patients experienced severe EDS. By the first follow-up (median [IQR], 49 [28-94] days), mean (SD) ESS scores were within the normal EDS range with ON-SXB for both subgroups (ie, ESS < 10; switch, 9.7 [5.5]; not-on-oxybate, 9.5 [5.2]); the majority reported normal levels of daytime sleepiness (switch, 56%; not-on-oxybate, 57%). Mean (SD) change in ESS score from baseline to follow-up was -1.6 [4.5] for switch and -3.1 [5.0] for not-on-oxybate groups. Conclusion Patients who initiated ON-SXB experienced improvements in daytime sleepiness regardless of prior TN-OXB use, and many achieved normal levels of daytime sleepiness in ≤2 months of starting ON-SXB. Support (if any) Avadel Pharmaceuticals
0751 Improvement in Sleepiness with Once-Nightly Sodium Oxybate in People with Narcolepsy Type 1 and Narcolepsy Type 2: A Specialty Pharmacy Data Analysis
Meskill, Sarah, Herpel, Laura, Thorpy, Michael, Ruoff, Chad, Carino, Diana, BUYSMAN, ERIN, Vu, Michelle, Abaluck, Brian, Gudeman, Jennifer , Ruoff, Chad , Ruoff, Chad M , Meskill, Sarah, Herpel, Laura Bogan, Buysman, Erin K. , Abaluck, Brian

Mayo Clinic

SLEEPJ | May 9, 2026 | Volume: 49 | Issue: Supplement_1 | Pages: A335-A335

10.1093/sleep/zsag091.0750 Get It

Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is approved to treat excessive daytime sleepiness (EDS) or cataplexy in patients ≥7 years of age with narcolepsy. Findings from 2 studies have demonstrated improvements in objective and subjective EDS with ON-SXB in patients with narcolepsy type 1 (NT1) or 2 (NT2) (NCT02720744, NCT06792708). To evaluate the effect of ON-SXB on EDS in a larger, more diverse narcolepsy patient population, changes in Epworth Sleepiness Scale (ESS) score were analyzed using specialty pharmacy data. Methods Demographic/clinical data were collected from Optum Frontier Therapies pharmacy for adults with NT1 or NT2 with ≥1 filled ON-SXB prescription, ≥1 ON-SXB clinical assessment, and ≥1 follow-up ESS score (6/1/2023-9/30/2024). ESS total scores were assessed at baseline and at each follow-up assessment after ON-SXB initiation. ESS assessment participation was voluntary. Data were analyzed descriptively and stratified by narcolepsy subtype. Results Of 452 patients identified, 195 had ≥1 follow-up ESS score and reported narcolepsy type (NT1, n=123 [63%; mean age, 38.6 years; female, 69%]; NT2, n=72 [37%; mean age, 40.7 years; female, 74%]). More patients with NT1 vs NT2 (72% vs 58%) had any prior oxybate use. Baseline concomitant stimulant/wake-promoting agent use was 58% and 64% for NT1 and NT2, respectively. Mean (SD) ESS total scores at baseline were 12.1 (5.7) and 12.2 (5.3) for patients with NT1 and NT2, respectively; 31% of NT1 and 33% of NT2 had severe EDS. For both subtypes, mean (SD) ESS scores were within the normal EDS range (≤10) by the first follow-up (median time, 52 days; NT1, 10.0 [5.5]; NT2, 9.6 [4.8]). At first follow-up, more than half of patients in the NT1 (55%) and NT2 (54%) subgroups achieved normal levels (ESS total score ≤10) of sleepiness, while 20% of NT1 patients and 10% of NT2 patients had severe EDS. Mean (SD) change from baseline in ESS score was -2.1 (4.3) and -2.6 (5.3) in the NT1 and NT2 subgroups, respectively. Conclusion In this real-world dataset, both NT1 and NT2 patients quickly experienced clinically meaningful improvements in ESS score after initiating ON-SXB. These results support ON-SXB as an effective EDS treatment, regardless of narcolepsy subtype. Support (if any) Avadel Pharmaceuticals
0722 Demographic and Clinical Characteristics of People Receiving Once-Nightly Sodium Oxybate Treatment: A Specialty Pharmacy Data Analysis
Ruoff, Chad, Thorpy, Michael, Herpel, Laura, Meskill, Sarah, Vu, Michelle, BUYSMAN, ERIN, Carino, Diana, Abaluck, Brian, Gudeman, Jennifer , Ruoff, Chad , Ruoff, Chad M , Herpel, Laura Bogan, Meskill, Sarah, Buysman, Erin K. , Abaluck, Brian

Mayo Clinic

SLEEPJ | May 9, 2026 | Volume: 49 | Issue: Supplement_1 | Pages: A321-A322

10.1093/sleep/zsag091.0721 Get It

Abstract Introduction Once-nightly sodium oxybate (ON-SXB [LUMRYZ™]) is approved to treat excessive daytime sleepiness (EDS) or cataplexy in patients ≥7 years of age with narcolepsy. Real-world demographic/clinical characteristics and treatment adherence in patients with narcolepsy who received ON-SXB from a specialty pharmacy were assessed. Methods Baseline demographic/clinical data were collected from Optum Frontier Therapies pharmacy for patients with ≥1 filled ON-SXB prescription, ≥1 ON-SXB-related clinical assessment, and baseline Epworth Sleepiness Scale (ESS) score from 6/1/2023-9/30/2024. Adherence (≥80% of days covered) was assessed for patients with ≥3 months of ON-SXB use. Data were stratified by narcolepsy subtype (narcolepsy type 1 [NT1] and 2 [NT2] when available) and prior oxybate use (transitioned from prior oxybate therapy to ON-SXB ≤30 days of index [switch]/were oxybate-naive or discontinued oxybate >30 days before index [not-on-oxybate]). Data were analyzed descriptively. Results 452 patients were identified (NT1, 55%; NT2, 37%; NT unknown, 9%; switch, 40%; not-on-oxybate, 60% [oxybate-naive, n=147/271]). Mean (range) age was 38.9 (16.0-88.0) years. Most patients were female (68%) and had commercial insurance (78%). Overall, 67% of patients had prior oxybate use (NT1, 72% [n=179/247]; NT2, 59% [n=98/166]; switch, 100%; not-on-oxybate, 46% [n=124/271]); for these patients, the most common oxybate (65%) was mixed-salt oxybates (NT1, 61%; NT2, 70%; switch, 61%; not-on-oxybate, 70%). Overall, 64% of patients used stimulants/wake-promoting agents (WPAs) (NT1, 64%; NT2, 65%; switch, 60%; not-on-oxybate, 67%). Overall, the mean (SD) baseline ESS score was 12.0 ([5.5]; NT1, 11.7 [5.5]; NT2, 12.5 [5.3]; switch, 11.0 [5.7]; not-on-oxybate, 12.7 [5.3]). At baseline, 29% of patients experienced severe EDS (ESS score ≥16: NT1, 26%; NT2, 30%; switch, 20%; not-on-oxybate, 34%). Of 269 patients with ON-SXB use ≥3 months, 84% (NT1, 84%; NT2, 89%; switch, 94%; not-on-oxybate, 76%) demonstrated adherence. Conclusion Patients not on an oxybate had the highest baseline ESS scores and proportion with severe EDS, despite greater stimulant/WPA utilization. Patients with NT1 used oxybates more frequently than those with NT2 despite those with NT2 having higher baseline ESS scores and a greater proportion having severe EDS, suggesting oxybates merit earlier consideration in patients with NT2. Most patients demonstrated ON-SXB adherence, indicating they would likely receive full therapeutic benefit. Support (if any) Avadel Pharmaceuticals
Addressing the needs of nano-rare patients: the n-Lorem experience
Crooke, Stanley T. , Glass, Sarah, Gleeson, Joseph G, Mignon, Laurence, Skourti-Stathaki, Konstantina , Douville, Julie , Knutsen, Megan, Pu, He, Bain, Jennifer M, Berry-Kravis, Elizabeth , Kim-McManus, Olivia, Eichler, Florian , Chung, Wendy K, Nagy, Amanda, Kaufmann, Horacio, Gonzalez-Duarte, Alejandra, Oskarsson, Björn, McCourt, Emily A. , Berry‐Kravis, Elizabeth , Nagy, Amanda , Leung, Nelson , Kaufmann, Horacio , Gleeson, Joseph G. , Mignon, Laurence, Bain, Jennifer , Shneider, Neil A. , McManus, Olivia Kim , Chung, Wendy K. , González-Duarte, Alejandra

Mayo Clinic

Nucleic Acids Research | May 8, 2026 | Volume: 54 | Issue: 10 | Pages: No page available

10.1093/nar/gkag504 | PMID 42227334 Get It

Abstract Patients with extremely rare pathogenic variants pose unique challenges to current healthcare systems. Nano-rare mutations have been defined as mutations with a known prevalence of <30 patients worldwide, but because of the small fraction of humans who have undergone genetic testing, neither the precise prevalence of individual mutations nor the total prevalence of patients with nano-rare mutations is known. n-Lorem is a non-profit founded in 2020 with the mission of equitably discovering, developing, and providing bespoke experimental antisense oligonucleotides (ASOs) for free, for life, to patients with nano-rare mutations that are amenable to ASO treatment. In this perspective, we provide an overview of the n-Lorem processes and systems, the characteristics of the first 329 patients who have applied for treatment for whom initial assessment was completed and suitability for ASO treatment determined, and a summary of the results of ASO treatment for patients treated to date. Detailed data on individual patients and the overall clinical safety and tolerability profiles of the ASOs for which there are clinical data are the subjects of other manuscripts.
Web-Based Amblyopia Decision Support Tool
Summers, Allison I. , Hatch, S.W., Wiecek, Emily , Hribar, Michelle R. , Robinson, Julianne L., Chen, Angela M., Kulp, Marjean T., Chen, Debora M. Lee, Repka, Michael X., Roberts, Tawna L. , Wallace, David K. , Vricella, Marilyn, Chang, Steven, Stutz, Kathleen M., Beaulieu, Wesley T., Kraker, Raymond T., Cotter, Susan A., Holmes, Jonathan M., Weise, Katherine K., Pineles, Stacy L., (PEDIG), Pediatric Eye Disease Investigator Group, Hatt, Sarah R. , Chen, Angela M. , Kulp, Marjean Taylor , Repka, Michael X. , Wang, Jingyun, Beaulieu, Wesley T , Kraker, Raymond T. , Cotter, Susan A. , Holmes, Jonathan M.

Mayo Clinic

JAMA Ophthalmology | May 7, 2026 | Volume: 144 | Issue: 6 | Pages: 545

10.1001/jamaophthalmol.2026.1095 | PMID 42096234 Get It

Importance Amblyopia is the leading cause of monocular decreased best-corrected vision in children. Early detection and intervention are key for optimal treatment outcomes; however, limited access to pediatric eye specialists may hinder timely care and affect visual outcomes. Given the shortage of specialty-trained eye care professionals in the US, there is need to support comprehensive eye care professionals who are willing to examine and treat children with amblyopia. Objective A panel from the Pediatric Eye Disease Investigator Group synthesized relevant literature and incorporated consensus opinion where direct evidence was lacking to create the Amblyopia Navigator Decision-Support Instrument, a free, web-based amblyopia decision support tool for eye care professionals. Evidence Review The decisions related to optimal diagnostic measures, pass/refer criteria, and management recommendations were informed by 147 publications. In areas where direct evidence was lacking, guidance was supplemented with clinical trial protocols or existing professional guidelines. When data were conflicting or unavailable, recommendations were established through committee consensus. A single reviewer independently performed standardized (though not systematic) literature reviews to avoid missing pertinent recent publications. Findings Presented are the process used, supporting evidence, and recommendations for testing methods, refractive correction, amblyopia treatment options, treatment adjustments, and monitoring schedules. Conclusions and Relevance Because amblyopia is common and typically responds well to treatment, decision support tools that optimize its management could increase access to pediatric eye care by facilitating earlier detection, enabling broader participation of primary eye care professionals, and ultimately improving visual outcomes. Through this work and the development of the forthcoming free, web-based application version, Amblyopia Navigator Decision-Support Instrument, the Pediatric Eye Disease Investigator Group has created decision support tools designed to assist optometrists and ophthalmologists in the care of children aged 3 to 17 years with amblyopia.
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma
McGuirk, Joseph P. , Ghobadi, Armin , Bachier, Carlos, Shaughnessy, Paul , Awan, Farrukh T. , Maakaron, Joseph E., Bishop, Michael R. , Ho, P. Joy , Tam, Constantine S., Dickinson, Michael J., Darrah, Justin , Ross, Ainsley, Williams, Leah M., Pan, Chenyi , Stevens, William N., Serwer, Laura, Nguyen, Thao, Terrett, Jonathan, Kalaitzidis, Demetrios, Ma, Anna, Xu, Huansheng, Benton, Mark, Weaver, Annie, Cohen, S, Awan, Farrukh T , Dickinson, Michael , Waller, Edmund K , Murthy, Hemant S , Maziarz, Richard Thomas , Cheah, Chan Yoon , Bishop, Michael Russell , McGuirk, Joseph , Ghobadi, Armin , Maakaron, Joseph E. , Dickinson, Michael , Waller, Edmund K. , Murthy, Hemant S. , Williams, Leah M. , Serwer, Laura , Terrett, Jonathan A. , Weaver, Alana M., Beaussant, Sarah cohen , Cheah, Chan Y.

Mayo Clinic

Blood Advances | May 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020123 | PMID 42085626 Get It

This multicenter, single-arm, phase 1/2 study evaluated the safety and efficacy of CD19-directed allogeneic chimeric-antigen-receptor (CAR) immunotherapy CTX110 in adult patients with relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (NHL). Patients received 1 or 2 treatment courses: standard lymphodepletion, followed by 1 CTX110 infusion at dose levels (DLs) 1-4 (3-60 × 107 CAR T-cells; dose escalation, N=32), or 2 infusions at DL4 on days 1 and 35 (cohort expansion, N=31). Primary endpoints in dose escalation and cohort expansion were incidence of dose-limiting toxicities and objective response rate, respectively. CTX110 was administered to 63 heavily pretreated patients: 59% primary refractory, 43% with ≥3 prior treatment lines. Among 57 patients whose first infusion was DL≥3, rates of objective and complete response (CR) were 65% and 39%, respectively. Among 22 patients achieving CR, 5 (23%) had ongoing CR at data cutoff, with 15-50 (median 34) months follow-up. The 2-infusion regimen appeared to prolong response duration compared to 1 infusion (hazard ratio 0.65). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were reported in 54% and 13% of treated patients, respectively, including 2 grade ≥3 cases each. The most common grade ≥3 adverse events were neutropenia (59%), and anemia and thrombocytopenia (35% each). Serious adverse events occurred in 32% of treated patients, including CRS (14%), ICANS (8%), and febrile neutropenia (6%). In this r/r NHL population, CTX110 was well-tolerated, resulting in clinically meaningful responses at DL≥3, with a second infusion demonstrating evidence of further clinical benefit. This trial (NCT04035434) was registered at www.clinicaltrials.gov.
E-cigarette use in vehicles: factors associated with secondhand exposure and behaviour from a US young adult sample in 2024
Elizabeth, K. , Watkins, Joslynn A., Iskra, Madison L. , Koris, Kristiann , Graham, Amanda L. , Soule, Eric K. , Hair, Elizabeth C. , Do, Elizabeth K , Graham, Amanda L , Soule, Eric K , Hair, Elizabeth C , Cha, Sarah

Mayo Clinic

Tobacco Control | May 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: tc-2025-059919

10.1136/tc-2025-059919 | PMID 42086323 Get It

Background This study investigates factors associated with electronic cigarette (e-cigarette) use and secondhand exposure in vehicles among US youth and young adults. Methods Data were collected from an online panel survey of individuals (N=3482, aged 15–25 years) from July to December 2024. Analyses included those who reported using any tobacco product in the past 30 days and answered items measuring exposure to (N=2600) and/or use of e-cigarettes in vehicles (N=2366). Logistic regression models assessed predictors of e-cigarette use and exposure in vehicles, including demographic, psychosocial and tobacco use characteristics. Results Among all participants, 67.1% reported e-cigarette use in the past 30 days. Of those reporting current e-cigarette use (N=2336), 60.6% reported using their e-cigarette/vape while travelling by car in the past 30 days. Of those who answered the question measuring exposure to e-cigarette use in vehicles (N=2600), 69.3% reported being in a vehicle where someone was using e-cigarettes. Higher nicotine dependence and residence in small metro and non-metro areas were associated with greater odds of using e-cigarettes in vehicles. Just meeting basic expenses or meeting needs with a little left, household tobacco use and residence in small metro areas were associated with greater odds of secondhand e-cigarette exposure. Discussion Public health interventions should place a strong focus on education and increasing public awareness of the health consequences of e-cigarette use in vehicles to protect bystanders from secondhand e-cigarette exposure.
Adipose‐derived and bone marrow aspirate concentrate injections for osteoarthritis: A scoping review
OLIVEIRA, LEONARDO P. , Lear, Aaron , Stokes, Derek , Chamberlain, Rachel, Agnew, Megan, Kliethermes, Stephanie, Sund, Sarah , Shapiro, Shane, Mautner, Kenneth, Stokes, Derek , Tiu, Timothy , Mautner, Kenneth R , Elphingstone, Joseph W. , Chamberlain, Rachel, Price, David, Agnew, Megan, Kliethermes‌, Stephanie , Christensen, Leslie , Mautner, Kenneth

Mayo Clinic

PM&R | May 2, 2026 | Volume: 18 | Issue: S2 | Pages: No page available

10.1002/pmrj.70147 | PMID 42068232 Get It

Abstract Background Osteoarthritis is a leading cause of disability worldwide, and cell‐based treatments including adipose‐derived and bone marrow aspirate have been sought by the lay and medical community as treatment options. Objective To perform a scoping review of published literature on cell‐based injections allowed by the U.S. Food and Drug Administration for the treatment of osteoarthritis to synthesize existing evidence and identify research gaps for future evaluation. Methods A comprehensive search of five databases was executed from inception through January 2, 2025. Studies that met the inclusion criteria were original research studies written in English on Food and Drug Administration‐allowed cell‐based treatments in adults with osteoarthritis of any joint. Results The database search yielded 4257 unique records. After screening, 84 studies met the inclusion criteria, encompassing 9996 patients and a total of 10,508 procedures. The primary research study designs were cohort studies ( n = 62), focused on treatment of knee osteoarthritis ( n = 63), and described bone marrow aspirate ( n = 42) and adipose‐derived ( n = 42) treatments. Postprocedure monitoring ranged from 6 weeks to 5 years, with most studies ≤1 year ( n = 59). Patient‐reported outcomes were reported in 83 of 84 studies; few provided imaging outcomes including magnetic resonance imaging ( n = 9) or radiographs ( n = 2). Conclusion This review identified limited randomized controlled trials, limited studies outside the knee, limited description of cell‐based treatments, and treatment protocols, along with inconsistent patient‐reported outcomes limited to 1 year in most studies. We propose establishing reporting guidelines in research on cell‐based therapies.
A Survey-Based Study of Reproductive Health Practices by Immunologists of the Clinical Immunology Society in Patients with Inborn Errors of Immunity
Galant-Swafford, Jessica , Gans, Melissa, Huangpo, Tracy, Han, Sarah, Ward, Brant, Vinh, Donald, Chapdelaine, Hugo, Ackerman, Kevin, Rosenberg, Daniel, Squire, Jacqueline, Hobson, Jessica, Jongco, Art, Ahmed, Aisha, Ale, Hanadys, Kim, Vy, Barmettler, Sara , Piazza, Megan, Pachul, Jessica Willett, Fernandes, Monica, Nguyen, Ashley, Freeman, Catherine , Schutt, Madeline, Raje, Nikita , Bayer, Diana, Gunderman, Lauren, Trujillo, Vivian Hernandez-, Freeman, Alexandra, Gans, Melissa D. , Ward, Brant R. , Vinh, Donald Cuong , Chapdelaine, Hugo , Rosenberg, Daniel L. , Almarzooqi, Farida , Peng, Xiao P. , Ale, Hanadys , Kim, Vy Hong-Diep, Piazza, Megan S. , Gunderman, Lauren M. , Hernandez-Trujillo, Vivian Pilar, Hajjar, Joud

Mayo Clinic

Journal of Human Immunity | May 1, 2026 | Volume: 2 | Issue: CIS2026 | Pages: No page available

10.70962/cis2026abstract.20 Get It

Introduction Individuals with inborn errors of immunity (IEI) are increasingly reaching reproductive age, yet guidance on fertility preservation, genetic counseling, medication adjustments in pregnancy and breastfeeding, monitoring for complications, and multidisciplinary coordination is lacking. This joint effort between two committees of the Clinical Immunology Society (CIS), the Women of the Clinical Immunology Society (WCIS) and the Adult Immune Deficiency Committee (AID) survey aimed to characterize current reproductive care practices for IEI patients. Methods A survey was disseminated to 809 CIS members. The response rate was 6.43% (52 respondents). The 24-item questionnaire addressed management of pregnancy in IEI, medications adjustment, participation in hematopoietic stem cell transplant (HSCT) care and fertility preservation, and maternal/neonatal outcomes. Results Because survey items were optional, the number of respondents varies by question. Forty-two participants completed core items: 64% (27/42) allergists/immunologists, 71% (30/42) practicing at academic centers, and 48% (20/42) with >50% immunology-focused practices. Most respondents (78%, 41/52) currently or previously cared for pregnant/planning IEI patients. Preconception counseling was common (90%, 37/41), yet only 2% (1/41) have access to a formal reproductive multidisciplinary team. Among clinicians involved in HSCT care, 45% (13/29) referred patients for fertility preservation. More than half, 52% (22/42), observed reduced fertility in IEI patients, and 56% (20/36) observed adverse maternal outcomes. Medication management varied: 61% (24/39) discontinued known teratogenic medications, and 64% (25/39) adjusted dosing during pregnancy. Regarding immunoglobulin replacement therapy, 79% adjusted dosing based on IgG levels and 42% increased dosing by trimester. Conclusions This CIS survey reveals practice variability and notable gaps in reproductive health support for individuals with IEIs. Due to the relatively low response rate, generalizability across providers and practice settings is challenging. However, the results of this survey suggest that although most clinicians provide preconception counseling and manage IgG and immunomodulatory therapy during pregnancy, formal multidisciplinary structures are rare. High rates of reported fertility concerns and maternal complications underscore the need for enhanced collaboration with obstetrics/gynecology and the development of structured, evidence-based, multidisciplinary guidelines for reproductive care in IEI. Tabular data are included as downloadable supplement files.